Intelligence Feed event · Policy · 2026-07-31

    Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy

    Question

    Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy

    Direct answer

    The positive AdCom vote is a critical de-risking event for Replimune. While the FDA is not required to follow the committee's recommendation, a 10-3 margin is typically a strong indicator of approval. This therapy addresses a significant unmet need in patients who have failed standard-of-care PD-1 inhibitors.

    Original publisher
    Market Ontology
    Evidence through
    2026-07-31
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy”, revision 1, evidence through 2026-07-31. https://marketontology.com/market-events/2026-07-31/replimune-gains-favorable-10-3-fda-advisory-vote-for-melanoma-therapy-03f309

    POLICY
    Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy
    The positive AdCom vote is a critical de-risking event for Replimune. While the FDA is not required to follow the committee's recommendation, a 10-3 margin is typically a strong indicator of approval. This therapy addresses a significant unmet need in patients who have failed standard-of-care PD-1 inhibitors.
    REPL
    Impact
    70
    JUL 31
    SIG
    90%
    REPL
    Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy
    The positive AdCom vote is a critical de-risking event for Replimune. While the FDA is not required to follow the committee's recommendation, a 10-3 margin is typically a strong indicator of approval. This therapy addresses a significant unmet need in patients who have failed standard-of-care PD-1 inhibitors.
    → Increased probability of FDA approval leading to binary valuation re-rating.
    Impact
    The positive AdCom vote is a critical de-risking event for Replimune. While the FDA is not required to follow the committee's recommendation, a 10-3 margin is typically a strong indicator of approval. This therapy addresses a significant unmet need in patients who have failed standard-of-care PD-1 inhibitors.
    Affected
    REPL
    Transmission
    Increased probability of FDA approval leading to binary valuation re-rating.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month